Fibrogen’s pamrevlumab drug has advanced to Phase 3 clinical trials. Its been proven to halt IPF disease progression and “ease fibrosis in IPF patients” in previous Phase 2 studies. Phase 3 will expand the number of people in the trials.
There are actually two phase 3 studies call ZEPHUS and ZEPHUS2. Both are actively recruiting IPF patients ages 40-85 who have been treated with Esbriet (pirfenidone) or Ofev (nintedanib) but stopped using them.
IPf patients are being recruited for the ZEPHUS trial in the United States, Australia, Argentina, Taiwan, Chile, and the Republic of Korea. (Trial ID NCT03955146)
IPF Patients for ZEPHUS2 are being recruited in Georgia, Italy, Hungary and Lebanon. (Trial ID NCT04419558)
To view details of the trials, cities where clinics are and how to apply go:
Pulmonary Fibrosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.